Skip to main content

ALX Oncology Holdings Inc

corporate_fare Company Profile

ALX Oncology Holdings Inc

ALXO·NASDAQ·Life Sciences·CIK 0001810182

We are a clinical-stage biotechnology company focused on developing new therapies to treat cancer and extend patients' lives. Our clinical pipeline includes two product candidates: evorpacept, a CD47 blocker, and ALX2004, an epidermal growth factor receptor (EGFR)-targeted antibody drug candidate (ADC). Our primary product candidate, evorpacept, is designed to be a foundational therapy for immuno-oncology in patients whose cancer over-expresses CD47. Evorpacept is currently being evaluated in the Phase 2 ASPEN-09-Breast clinical trial in combination with trastuzumab and chemotherapy for patients with metastatic HER2-positive breast cancer. It is also being studied in clinical trials with other targeted anti-cancer antibodies. Cancer cells use CD47, a cell surface protein, as a "don't eat me" signal to avoid being engulfed by macrophages. We are developing evorpacept as a next-generation checkpoint inhibitor with a high affinity for CD47, aiming to avoid the blood-related toxicities seen with other CD47 blocking methods. Our second pipeline candidate, ALX2004, is a new EGFR-targeted antibody-drug conjugate with a distinct mechanism of action, which entered a Phase 1 clinical trial in August 2025.

ALX Oncology Holdings Inc (NASDAQ:ALXO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for ALXO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-15, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for ALXO spans 8-K, 10-K, SCHEDULE 13D/A, 4.

Recent high-impact activity:

  • ALX Oncology Exchanges 13.35M Shares for Pre-Funded Warrants with Blackstone, RA Capital, venBio
  • Nature Medicine Publishes ASPEN-06 Data: Evorpacept Shows 40.3% ORR in HER2+ Gastric Cancer
  • ALX Oncology Q2 Loss Narrows to $0.13/Share, Cash Runway Extended to H1 2028
  • ALX Oncology Narrows Q2 Loss, Extends Cash Runway to First Half of 2028, and Sets Mid-2027 Evorpacept Readout
  • Co-founder and Chairman Corey Goodman Resigns from ALX Oncology Board

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$101.69M
Diluted EPS
-$1.90
Op. Cash Flow
-$84.14M
Free Cash Flow
-$84.35M
Operating Income
-$104.02M
Cash & Equivalents
$16.37M
Total Debt
$9.75M
Debt / Equity
0.38×
Shares Outstanding
54.39M sh
Source: 10-K · filed 2026-03-09 · accession 0001193125-26-098454

Short Interest & Short Volume

4.43 days to cover

FINRA reported short interest of 6,166,023 shares in ALXO as of the October 30, 2026 settlement, a 3.2% increase from the prior period — about 4.4 days to cover at its recent average daily volume. On November 20, 2026, 56.5% of ALXO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)6,166,023 shares as of October 30, 2026
Change vs prior period▲ 3.2%
Days to cover4.43 at avg daily volume of 1,392,864
Daily short volume (FINRA facilities)56.5% of 374,077 shares on November 20, 2026
5-day average short volume22.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$0.994 -2.55% today
52-week range · as of 2026-10-15 $0.8617 – $2.66
Market cap
$137.03M
Volume
997.7K (0.8× avg)
3-mo avg 1.3M
Live data · 2026-11-21 19:58 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ALXO - Latest Insights

ALXO
Oct 15, 2026, 4:55 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.9709
Real-time Price: $0.994 info
Change: +$0.0231 (+2%) info
Market Cap: $137.031M info
ALXO
Sep 28, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.30
Real-time Price: $0.994 info
Change: -$0.306 (-24%) info
Market Cap: $137.031M info
ALXO
Aug 06, 2026, 8:16 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.92
Real-time Price: $0.994 info
Change: -$0.926 (-48%) info
Market Cap: $137.031M info
ALXO
Aug 06, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.92
Real-time Price: $0.994 info
Change: -$0.926 (-48%) info
Market Cap: $137.031M info
ALXO
Jun 30, 2026, 4:03 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.07
Real-time Price: $0.994 info
Change: -$1.08 (-52%) info
Market Cap: $137.031M info
ALXO
Jun 30, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.07
Real-time Price: $0.994 info
Change: -$1.08 (-52%) info
Market Cap: $137.031M info
ALXO
Jun 26, 2026, 4:03 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $2.04
Real-time Price: $0.994 info
Change: -$1.05 (-51%) info
Market Cap: $137.031M info
ALXO
Jun 26, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.04
Real-time Price: $0.994 info
Change: -$1.05 (-51%) info
Market Cap: $137.031M info
ALXO
May 08, 2026, 8:00 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.90
Real-time Price: $0.994 info
Change: -$0.901 (-48%) info
Market Cap: $137.031M info
ALXO
May 07, 2026, 8:07 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $2.09
Real-time Price: $0.994 info
Change: -$1.10 (-53%) info
Market Cap: $137.031M info
ALXO
Apr 13, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.70
Real-time Price: $0.994 info
Change: -$0.7072 (-42%) info
Market Cap: $137.031M info
ALXO
Mar 09, 2026, 4:03 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $2.13
Real-time Price: $0.994 info
Change: -$1.14 (-53%) info
Market Cap: $137.031M info
ALXO
Feb 27, 2026, 8:13 AM EST
Source: Unknown
Importance Score:
9
Price at Filing: $2.48
Real-time Price: $0.994 info
Change: -$1.48 (-60%) info
Market Cap: $137.031M info
ALXO
Feb 27, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.48
Real-time Price: $0.994 info
Change: -$1.48 (-60%) info
Market Cap: $137.031M info
ALXO
Feb 27, 2026, 8:00 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $2.48
Real-time Price: $0.994 info
Change: -$1.48 (-60%) info
Market Cap: $137.031M info
ALXO
Feb 04, 2026, 9:03 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $2.19
Real-time Price: $0.994 info
Change: -$1.20 (-55%) info
Market Cap: $137.031M info
ALXO
Feb 04, 2026, 4:15 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $2.19
Real-time Price: $0.994 info
Change: -$1.20 (-55%) info
Market Cap: $137.031M info
ALXO
Jan 30, 2026, 4:02 PM EST
Filing Type: 424B5
Importance Score:
9
Price at Filing: $1.74
Real-time Price: $0.994 info
Change: -$0.746 (-43%) info
Market Cap: $137.031M info
ALXO
Jan 30, 2026, 8:36 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.70
Real-time Price: $0.994 info
Change: -$0.706 (-42%) info
Market Cap: $137.031M info
ALXO
Jan 30, 2026, 8:22 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.55
Real-time Price: $0.994 info
Change: -$0.556 (-36%) info
Market Cap: $137.031M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets